Sylvestre Diana L, Litwin Alain H, Clements Barry J, Gourevitch Marc N
Department of Medicine, University of California, San Francisco, CA, USA.
J Subst Abuse Treat. 2005 Oct;29(3):159-65. doi: 10.1016/j.jsat.2005.06.002.
Although most cases of hepatitis C virus (HCV) infection are associated with injection drug use, there are few data regarding the impact of putative barriers such as psychiatric disease and intercurrent drug use on HCV treatment outcomes. To define the impact of characteristics often cited as reasons for withholding HCV treatment, we studied HCV treatment in a real world sample of 76 recovering heroin users maintained on methadone. Overall, 21 (28%) had a sustained virological response and 18 (24%) discontinued treatment early. Although there was a modest decrement in response rates in patients reporting a preexisting psychiatric history (p = .01), neither intercurrent drug use nor short duration of pretreatment drug abstinence led to significant reductions in virological outcomes (p = .09 and p = .18, respectively.) We conclude that injection drug users can be safely and effectively treated for HCV despite multiple barriers to treatment when they are treated in a setting that can address their special needs.
尽管大多数丙型肝炎病毒(HCV)感染病例与注射吸毒有关,但关于精神疾病和并发药物使用等假定障碍对HCV治疗结果影响的数据很少。为了确定常被视为推迟HCV治疗原因的特征的影响,我们在一个以美沙酮维持治疗的76名康复海洛因使用者的真实样本中研究了HCV治疗。总体而言,21例(28%)有持续病毒学应答,18例(24%)提前终止治疗。虽然报告有既往精神病史的患者应答率有适度下降(p = 0.01),但并发药物使用和治疗前药物戒断时间短均未导致病毒学结果显著降低(分别为p = 0.09和p = 0.18)。我们得出结论,尽管存在多种治疗障碍,但在能够满足其特殊需求的环境中接受治疗时,注射吸毒者可以安全有效地接受HCV治疗。